Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
McKinsey
Harvard Business School
Colorcon
Mallinckrodt

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,925,244

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,925,244
Title:Treatment of warts in non-immunosuppressed patients
Abstract: A method for treating warts includes administering to a patient with warts a composition having an autologous, matched allogenic, donor tissue source of mixed, hematological, pleuripotent, ISPC derived or harvested or induced mesenchymal type stem cells and/or filgrastim, derivatives, bioequivalents, and pharmaceutically effective salts thereof. Patients include both non-chemotherapy or non-immunosuppressed patients, as well as chemotherapy or immunosupressed patients with warts of non-responsive cutaneous type. The treatment leads to resolution of warts and/or a change in their response to laser therapy or standard treatments previously shown not to be effective.
Inventor(s): Chez; Michael (Granite City, CA)
Assignee:
Application Number:15/045,294
Patent Claims:1. A method for treating warts, comprising: administering to a patient with warts a composition comprising filgrastim, derivatives, bioequivalents, and pharmaceutically effective salts thereof, and allowing the warts to be treated, wherein the warts disappear or respond to laser therapy; wherein said patient is non-immunocompromised and without neutropenia; and wherein said administering comprises an injection of filgrastim that is administered for about 3-5 days subcutaneously.

2. The method according to claim 1, wherein said warts are cutaneous warts.

3. The method according to claim 1, wherein said warts are veneral warts.

4. The method according to claim 1, wherein the injection is administered at a dosage of about 100-500 micrograms per day.

5. The method according to claim 1, wherein the injection may be repeated at least once.

6. The method according to claim 1, wherein the warts are treated and disappear.

7. The method according to claim 1, wherein the warts are treated and respond to laser therapy.

8. The method according to claim 1, wherein the composition comprises filgrastim.

Details for Patent 9,925,244

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial 2038-04-28 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial 2038-04-28 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial 2038-04-28 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial 2038-04-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
AstraZeneca
McKinsey
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.